Tabrecta 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued 2 / 
affected 3  
amended 
on 
II/0002 
Update of section 4.8 of the SmPC  in order to add 
01/12/2022 
SmPC  and PL 
Not applicable 
hypersensitivity to the list of adverse drug reactions 
(ADRs)  with frequency uncommon, based on 
cumulative assessment of hypersensitivity cases in 
studies CINC280A2201,  CINC280X1101, 
CINC280X2102,  CINC280A2108,  CINC280A2103 
For more information, please refer to the Summary of 
Product Characteristics. 
1 Notifications are issued for type I  variations and Article 61(3) notifications (unless part of a group including a type II  variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II,  labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC  (Summary  of Product Characteristics), Annex II,  Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European  Union 
 
 
 
 
 
 
  
 
 
 
(post-DDI phase only), and CINC280A2105  (post-
DDI  phase only) and MAH global safety database. 
The Package Leaflet is updated accordingly 
C.I.4  - Change(s) in the SPC,  Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
IAIN/0001 
B.II.g.5.a  - Implementation of changes foreseen in 
24/08/2022 
n/a 
an approved change management protocol - 
Requires no further supporting data 
Page 2/2 
 
 
 
 
 
 
 
 
 
 
 
